Novo Nordisk is streamlining its operations in an effort to improve the speed of decision-making and to reallocate resources towards the company’s growth opportunities in diabetes and obesity. As part of the transformation, Novo Nordisk is reducing the global workforce by approximately 9,000 of the 78,400 positions in the company, with around 5,000 reductions expected in Denmark. According to the company, the transformation reflects competing in a more dynamic and consumer-driven obesity mark...